case study Spinal Cord Injury Patient Treated with Cell-based Therapy and CellSonic VIPP
Swetha Subramanian1*, Andrew Hague2
1StemRx
BioScience Solutions Pvt Ltd, Dr. Mahajan's
Hospital & ITC, Rabale, Navi Mumbai, India
2CellSonic, Manufacturers of Medical Equipment, UK
*Corresponding author: Swetha Subramanian, StemRx BioScience Solutions Pvt Ltd, Dr. Mahajan's Hospital & ITC, Rabale, Navi Mumbai, India. Tel: + 919987274620; +918898070904; Email: drpvmahajan@gmail.com
Received
Date: 29 May,
2018; Accepted Date: 12 June, 2018; Published Date: 20 June, 2018
Citation: Subramanian S, Hague A (2018) Spinal Cord Injury Patient Treated with Cell-based Therapy and CellSonic VIPP. Emerg Med Inves: 177. DOI: 10.29011/2475-5605.000077
Case Study
https://www.youtube.com/watch?v=kK3YY7Zk1ZQ&t=110s
The patient had a road traffic accident and sustained injuries in his spine in September 2017. He was paralyzed below the waist and was bedridden since the accident. He did not undergo any major treatment at his home country. He was brought to our hospital on a stretcher. With cell-based therapy and CellSonic VIPP plus neurorehabilitation, the patient was able to stand with the help of callipers within a month of treatment. This is tremendous improvement as the family was told that the boy will remain bedridden. He had developed bed sores due to lack of movement. With the combination treatment of cell-based therapy and CellSonic VIPP in the wound area, we could accomplish rapid healing of the sores. Overall the improvement is very encouraging.
After few months of follow up, we will look to publish this case. We have few more cases in the pipeline and we hope to publish them in reputed journals after the required follow up period.
Regards
Dr. Swetha Subramanian
Clinical Research Associate
StemRx BioScience Solutions Pvt Ltd,
Dr. Mahajan's Hospital & ITC
Rabale,Navi Mumbai - 400708
Web: www.stemrx.in
Email: drpvmahajan@gmail.com
Phone: + 919987274620, +918898070904
© by the Authors & Gavin Publishers. This is an Open Access Journal Article Published Under Attribution-Share Alike CC BY-SA: Creative Commons Attribution-Share Alike 4.0 International License. Read More About Open Access Policy.